Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,635,523

« Back to Dashboard
Patent 5,635,523 protects NORVIR and is included in one NDA. There have been two Paragraph IV challenges on Norvir. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for NORVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and nine patent family members in twenty-three countries.

Summary for Patent: 5,635,523

Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/417,879
Patent Claim Types:
see list of patent claims
Use;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbott
NORVIR
ritonavir
CAPSULE;ORAL020680-001Mar 1, 1996DISCNNo5,635,523*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,635,523

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,674,882 Retroviral protease inhibiting compounds<disabled in preview>
5,580,984 Retroviral protease inhibiting compounds<disabled in preview>
5,670,675 Retroviral protease inhibiting compounds<disabled in preview>
5,837,873 Intermediates of retroviral protease inhibiting compounds<disabled in preview>
5,354,866 Retroviral protease inhibiting compounds<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,635,523

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0402646Jul 22, 1998
ItalyMI913081May 20, 1992
European Patent Office0674513Oct 25, 1995C00674513Switzerland<disabled>
Spain2088839Oct 01, 1996
Israel99952Jun 29, 2000
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc